Share
Export Citation
APA
MLA
Chicago
Harvard
Vancouver
BIBTEX
RIS
Universitas Hasanuddin
Research output:Contribution to journal›Article›peer-review
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial
Matthews G.
Lancet HIV
Q1Published: 2024Citations: 27
Abstract
Sourced directly from Elsevier Scopus. No OpenAlex abstract available.
Access to Document
10.1016/S2352-3018(24)00089-4Other files and links
- Link to publication in Scopus
- Open Access Version Available
Fingerprint
DolutegravirSciences
DarunavirSciences
MedicineSciences
Antiretroviral therapySciences
VirologySciences
Nucleoside Reverse Transcriptase InhibitorSciences
Human immunodeficiency virus (HIV)Sciences
Reverse-transcriptase inhibitorSciences
TenofovirSciences
Viral loadSciences